Cell-Based Therapies: The Nonresponder. (25th September 2018)

• Record Type: Journal Article
• Authors: Caplan, Arnold I.
• Is Part Of: Stem cells translational medicine. Volume 7:Number 11(2018)
• Page Start: 762
• Page End: 766
• Publication Date: 2018-09-25
• Subjects: Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.18-0074
• Languages: English
• ISSNs: 2157-6564

Abstract

Summary : Cell-based therapies have come of age and several phase III trials are now being conducted. Cell-based therapies, especially involving mesenchymal stem cells (MSCs), have substantial nonresponder rates, as has been reported in some current clinical trials. This high rate is expected as the MSCs are neither tuned for each of the diseases that are being treated nor for the huge variance in the genetics and response characteristics of the individual patients being treated. Such nonresponders might be used as a control group, thus eliminating the need for placebo controls.